On Monday, Canadian Solar Inc. (NASDAQ:CSIQ)’s shares declined -4.62% to $37.06.
Canadian Solar Inc. (CSIQ) declared that Natixis, New York Branch/Norddeutsche Landesbank Gironzentrale, New York Branch/Cooperative Centrale Raiffeisen-Boerenleenbank B.A./”Rabobank Nederland,” New York Branch will provide the company with up to C$53.5 Million (USD$44.4 Million) in non-recourse, construction plus term financing. The loan facility will finance the 10 MW utility-scale solar power project, “Illumination,” located in the town of Scugog, Ontario, which is being attained by DIF Infra 3 RE Canada Limited.
Developed by Canadian Solar, the solar power plant is predictable to be in commercial operation by the fourth quarter of 2015. The project has been awarded a 20-year power purchase contract by the Ontario Power Authority under Ontario’s Feed-In-Tariff program.
Canadian Solar Inc., together with its auxiliaries, designs, develops, manufactures, and sells solar wafers, cells, and solar power products worldwide. The company operates in two segments, Module and Energy. Its products comprise various solar modules that are used in residential, commercial, and industrial solar power generation systems.
Splunk Inc (NASDAQ:SPLK)’s shares dropped -4.58% to $67.03.
Splunk Inc (SPLK) will report results for its fiscal first quarter ended April 30, 2015 on Thursday, May 28, 2015. The results will be comprised of in a press release with accompanying financial information that will be released after market close and posted on the Splunk Investor Relations website.
Splunk’s executive administration team will host a conference call startning at 1:30 p.m. PT (4:30 p.m. ET) to talk about financial results and business highlights.
Splunk, Inc. provides software products that enable organizations to gain real-time operational intelligence in the United States and internationally. The companys products enable users to collect, index, search, explore, monitor, and analyze data regardless of format or source users. It offers Splunk Enterprise, a machine data engine with collection, indexing, search, reporting analysis, alerting, monitoring, and data administration capabilities; and Splunk Cloud service.
At the end of Monday’s trade, Clean Diesel Technologies, Inc. (NASDAQ:CDTI)‘s shares dipped -4.57% to $2.09.
Clean Diesel Technologies, Inc. (CDTI) declared it has signed a contract with a national private label for distribution of CDTi’s DuraFit(TM) diesel particulate filters (DPFs). Under the agreement, DuraFit DPFs will be distributed into the heavy and medium duty vehicle aftermarket for a period of up to 3 years. First shipments to the national private label distributor, whose name is being withheld in accordance with the agreement, are predictable to start in the 2nd quarter.
Designed and manufactured in North America, DuraFit DPFs are exact-fit original equipment manufacturer (OEM) replacements that meet or exceed OEM emissions requirements. DuraFit DPFs are fully-supported by a growing distributor network and field application specialists, and DuraFit DPFs distributed by the private label will have a 1-year unlimited mileage warranty.
Clean Diesel Technologies, Inc. manufactures and distributes light duty vehicle catalysts and heavy duty diesel emissions control systems and products to automakers, distributors, integrators, and retrofitters in the United States, Canada, Sweden, and the United Kingdom. It operates through two divisions, Catalyst and Heavy Duty Diesel Systems.
Hemispherx BioPharma, Inc (NYSEMKT:HEB), ended its Monday’s trading session with -4.37% loss, and closed at $0.241.
Hemispherx BioPharma, Inc (HEB) declared its financial results for the three months ended March 31, 2015. The net loss (counting non-cash effects) was about $3,445,000 or $(0.02) per share as contrast to a net loss of $3,836,000 or ($0.02) per share for the same three month period in 2014. Cash, cash equivalents and marketable securities were about $17,005,000 at March 31, 2015 as contrast to $16,108,000 as of December 31, 2014.
Our European partner, Hemispherx Biopharma Europe N.V./S.A., received formal notification from the European Commission [EU/3/15/1480-EMA/OD/310/14] approving its Orphan Medicinal Product Application for Ampligen(R), an experimental therapeutic, to treat Ebola Virus Disease (EVD).
Hemispherx Biopharma, Inc., a specialty pharmaceutical company, engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
